Premium
REGULATION of the CYCLIC GUANOSINE 3′‐5′ MONOPHOSPHATE SYSTEM IN HUMAN BRAIN TUMORS
Author(s) -
Frattola Lodovico,
Carenzi Angelo,
Cerri Cesare,
Kumakura Konosuke,
Trabucchi Marco
Publication year - 1976
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1976.tb04371.x
Subject(s) - cyclic guanosine monophosphate , phosphodiesterase , guanosine , cyclic nucleotide , pde10a , cyclase , enzyme , human brain , cyclic adenosine monophosphate , adenosine , cerebral cortex , nucleotide , guanosine monophosphate , biology , biochemistry , guanylate cyclase , endocrinology , chemistry , neuroscience , receptor , gene , nitric oxide
Several reports have suggested that cyclic guanosine 3′‐5′ monophosphate (cGMP) and cyclic 3′‐5′ adenosine monophosphate (cAMP) are involved in the regulation of cellular proliferation. Following our previous reports on the cAMP system in human brain tumors, we decided to investigate the cGMP system in the same pathological tissues by studying the activity of guanylate cyclase and cGMP‐phosphodiesterase (cGMP‐PDE). We found that the activity of both enzymes is lower in neurinomas and glioblastomas than in meningiomas or in normal cerebral cortex. Furthermore, the subcellular distribution of guanylate cyclase in human cerebral cortex differs from that of neurinomas and glioblastomas. On the basis of such ob servations we have discussed the possibility that the regulatory mechanism of the enzymes related to the cyclic nucleotide metabolism is altered in brain tumors.